Allergy Therapeutics (GB:AGY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allergy Therapeutics has announced its participation in the EAACI Congress 2024, where it will present significant research findings from its portfolio, including positive results from its Phase III G306 trial for a grass pollen allergy treatment and early-stage results for a novel peanut allergy vaccine candidate. The company’s presence at the congress underscores its dedication to advancing allergy treatments, with a focus on innovative immunotherapy approaches. No new price-sensitive information is expected to be disclosed during the event.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.